The U.S. Food and Drug Administration’s vaccine advisory panel on Tuesday voted 22 – 0 to authorize Moderna’s COVID-19 vaccines for children ages 6 to 11 and 12 to 17 despite the lack of short- and long-term safety data and no evidence children are at risk of serious illness.
The U.S. Food and Drug Administration’s (FDA) vaccine advisory panel today voted unanimously to recommend Moderna’s COVID-19 vaccine for children ages 6 to 17 after determining the benefits of the vaccine outweigh the risks for use.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 22 to 0 to recommend Moderna’s two-dose vaccine for 6- to 11-year-olds at half the strength of the adult version, and 22 to 0 in favor of authorizing the shot for 12- to 17-year-olds at the same strength as adults.
The FDA’s vaccine advisors will meet again on Wednesday to discuss amending Emergency Use Authorization (EUA) for Moderna’s COVID-19 vaccine to include the “administration of the primary series to infants and children 6 months through 5 years of age.”
The committee tomorrow also will discuss amending EUA of the Pfizer-BioNTech vaccine to “include the administration of the primary series to infants and children 6 months through 4 years of age.”
After VRBPAC makes its recommendations, the FDA will then decide whether to authorize Moderna and Pfizer’s vaccines for the suggested age groups.
During the public comment session of the meeting, individuals expressed concern over recommending a vaccine for an age group that has an almost zero risk of experiencing severe illness or death from COVID-19 and has already acquired a high level of natural immunity.
Read More: Breaking: FDA Panel Recommends Moderna Two-Dose COVID Vaccine for Kids Ages 6 to 17 Despite Serious Safety Concerns